ArticleReports of biochemistry & molecular biology2024
Evaluate the Serum of Irisin, Omentin-1, and Oxidative Status in Males with Prostatic Cancer.
Article in Reports of biochemistry & molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AdipoR1-AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis.Cell death & disease · 2026Article
- Possible Association of Glutathione S-Transferase Pi 1 (GSTP1) Gene Polymorphism in Iraqi Patients with Breast Cancer.Reports of biochemistry & molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is a classic public health problem in males and has broadly different levels of mortality and morbidity. As an endocrine gland, adipose tissue synthesizes and secretes a variety of bioactive peptides, such as irisin and omentin-1. Adipokines and oxidative stress potentially contribute to the proliferation of prostatic carcinoma cells. The relationship between irisin, omentin-1, and oxidative stress has not been widely investigated in prostate cancer. Therefore, the present research assessed whether there is a significant correlation between irisin and omentin-1 levels and oxidative status in prostate cancer individuals. Methods: The present research recruited 40 individuals diagnosed with prostate cancer and 40 healthy individuals for comparative purposes. All individuals underwent demographics, biochemicals, and serum adipokines (irisin and omentin-1) data analysis. Results: The means of total prostate-specific antigen (43.3±20.5 vs. 2.5±1.2) and free prostate-specific antigen (2.1±1.4 vs. 0.08±0.02) were highly significant increases in the prostate cancer patients than in the healthy individuals. Furthermore, the means of omentin-1 (31.6±12.8 vs. 23.5±14.1) and total oxidant stress (22.4±10.6 vs. 9.1±3.6) were highly significant increases in patients with prostate cancer than in healthy individuals. In contrast, the means of irisin (343.5±240.2 vs. 716.4±142.3) and total antioxidant capacity (2.2±1.2 vs. 3.3±1.3) were highly significant decreases in patients with prostate cancer than in healthy individuals. No significant relationship was demonstrated between all parameters in the two groups under study. Conclusions: The study findings indicate that irisin and omentin-1 could serve as biomarkers for predicting prostate cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.